Tempus AI's Cardiac Imaging Platform Receives FDA Clearance, Boosting Stock and AI Healthcare Advancements

Why Is Tempus AI Stock Trading Higher Today - Tempus AI (NASDAQ:TEM)

On Thursday, Tempus AI, Inc. TEM received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. The update allows the generation of T1 and T2 inline maps, further enhancing the device's cardiac MR image analysis capabilities. Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. Also Read: Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins AI-enabled radiology, like Tempus Pixel, enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights. Improving accuracy and efficiency empowers clinicians to make faster, more informed decisions and deliver personalized patient care. Unlike conventional MR images that show only brightness differences, T1 and T2 maps provide precise numerical values to card, whichissue characteristics, helping clinicians detect conditions such as fibrosis, inflaforation, or edema that may otherwise go undetected. With its newly cleared functionality, Tempus Pixel can now generate T1 and T2 inline maps directly from raw MRI data, even when the scanner itself does not produce them. It calculates values at every pixel across the image to create detailed DICOM maps for comprehensive tissue assessment. Tempus has developed and deployed a suite of advanced algorithms across radiology and pathology, helping physicians deliver more precision, personalized care. Its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data -- ranging from lung CT scans and chest X-rays to cardiac MRIs -- into Its platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology. This acquisition brought Tempus a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Its efforts. Price Action: TEM stock is up 14.89% at $89.80 at the last check on Thursday. Read Next: Starbucks Teams With AI Startup NomadGo To Automate Counting In 11,000 Stores -- CTO Says Goodbye To Manual Tallies Forever Image via Shutterstock TEMTempus AI Inc$89.1514.1%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum91.01Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Why Tempus AI Stock Soared Nearly 14% Higher Today | The Motley Fool

The AI heathcare tech specialist is about to put another product on the market. The stock of healthcare-focused artificial intelligence company Tempus AI (TEM 13.26%) was the cure for aching portfolios on Thursday. The company's share price ballooned by almost 14% on the back of a top regulator's decision about one of its products. That price pop was much more muscular than the S&P 500 index's 0.9% rise on the day. Before market open, Tempus AI announced that the U.S. Food and Drug Administration (FDA) had granted clearance for an upgraded version of its Tempus Pixel. This is a cardiac imaging platform that harnesses the company's AI technology to produce highly accurate images of a patient's heart. The healthcare tech company believes this will be beneficial not only to its own results but also for medical science in general. In the press release touting the news, Tempus AI quoted its senior vice president of AI applications, Chris Scotto Divetta, as saying that "This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful." Cardiac health is a significant segment of the broader healthcare market, so useful and effective next-generation imaging solutions are always welcome. This Tempus Pixel should be a winning product. What's also encouraging about Tempus AI is that it's not concentrating only on this segment or on imaging. Through both proprietary efforts and with strategic acquisitions, the company also offers AI-boosted analytical tools for evaluating diagnostics like CT scans and X-rays. The healthcare sector can really benefit from the effective deployment of AI, and this company seems as if it's on top of the game just now.

Tempus AI stock soars after FDA clearance for cardiac imaging platform By Investing.com

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock surged 16% Thursday morning following the company's announcement that it received 510(k) clearance from the U.S. Food and Drug Administration for its updated Tempus Pixel cardiac imaging platform. The regulatory approval enhances the AI-powered device's capabilities by allowing the generation of T1 and T2 inline maps for cardiac MR image analysis. These maps provide numerical values to cardiac tissue characteristics, helping clinicians detect conditions like fibrosis, inflammation, or edema that might otherwise remain undetected. Tempus Pixel can now generate these specialized maps directly from raw MRI data, even when the scanner itself doesn't produce them, creating detailed DICOM maps for comprehensive tissue assessment. "This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful," said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus. The company has been expanding its AI capabilities in medical imaging through strategic acquisitions, including Arterys in 2022 and more recently Paige, an AI company specializing in digital pathology. These acquisitions have brought additional datasets and technologies to strengthen Tempus' platform offerings in precision medicine. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Tempus AI, Inc. Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

Tempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. AI-enabled radiology, like Tempus Pixel, enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights. By improving accuracy and efficiency, it empowers clinicians to make faster, more informed decisions and deliver personalized patient care. Unlike conventional MR images that show only brightness differences, T1 and T2 maps provide precise numerical values to cardiac tissue characteristics, helping clinicians detect conditions such as fibrosis, inflammation, or edema, that may otherwise go undetected. With its newly cleared functionality, Tempus Pixel can now generate T1 and T2 inline map directly from raw MRI data, even when the scanner itself does not produce them, calculating values at every pixel across the image to create detailed DICOM maps for comprehensive tissue assessment. Tempus has developed and deployed a suite of advanced algorithms across radiology and pathology, helping physicians deliver more precision, personalized care. Its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data--ranging from lung CT scans and chest X-rays to cardiac MRIs-- into Tempus' platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus' efforts.